BSH 2022 | Optimal treatment sequencing in multiple myeloma
Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses treatment sequencing in multiple myeloma, underlining the importance of selecting the best available treatment in first line. Multiple lines of evidence have demonstrated that a patient’s duration of response (DOR) decreases after the first line of treatment. According to Prof. Pratt, the best combination for frontline therapy consists of quadruplet therapy with monoclonal antibodies, proteasome inhibitors, immunomodulatory imide drugs (IMiDs) and steroids. Following frontline therapy, Prof. Pratt explains that it is still necessary to determine the best consolidation and maintenance strategies. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
